Leukemia Clinical Trials in Detroit

Showing 1161-1180 of 1,440 trials

Sirolimus, Tacrolimus, and Antithymocyte Globulin in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer Who Are Undergoing Donor Stem Cell Transplant

NCT00691015

RATIONALE: Giving low doses of chemotherapy, monoclonal antibodies, and radiation therapy before a donor peripheral blood stem cell transplant helps stop the growth of cancer cells. It may also stop the patient's immune system from rejecting the donor's stem cells. The donated stem cells may replace the patient's immune cells and help destroy any remaining cancer cells (graft-versus-tumor effect). Sometimes the transplanted cells from a donor can also make an immune response against the body's normal cells. Giving tacrolimus, sirolimus, and antithymocyte globulin before and after transplant may stop this from happening. PURPOSE: This phase II trial is studying the side effects of giving sirolimus together with tacrolimus and antithymocyte globulin and to see how well it works in preventing graft-versus-host disease in patients with hematologic cancer who are undergoing donor stem cell transplant.

Chronic Myeloproliferative DisordersLeukemiaLymphoma+3 more

Barbara Ann Karmanos Cancer Institute48 participantsStarted May 2008

Detroit, Michigan, United States

COMPLETEDPhase 2< 1 mile

A Phase 2, Multicenter, Open-label Study of MEDI-551 in Adults With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)

NCT01466153

The overall purpose of the study was to determine if MEDI-551, when used in combination with salvage chemotherapy (bendamustine) in participants with relapsed or refractory CLL who are not eligible for Autologous Stem Cell Transplant (ASCT), had superior efficacy compared to rituximab in the same population.

Chronic Lymphocytic Leukemia (CLL)

MedImmune LLC183 participantsStarted Feb 2012

Birmingham, Alabama, United States • Burbank, California, United States • La Jolla, California, United States +51 more locations

Sirolimus, Tacrolimus, and Antithymocyte Globulin in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer Who Are Undergoing Donor Stem Cell Transplant

A Phase 2, Multicenter, Open-label Study of MEDI-551 in Adults With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)

Leukemia Trials in Other Cities

Study Evaluating Inotuzumab Ozogamicin In Acute Lymphocytic Leukemia

Weaning And Variability Evaluation

Cisplatin and Nab-paclitaxel for (N2) Defined NSCLC

Pharmacokinetics and Pharmacodynamics of Dexmedetomidine in Pediatrics Subjects

Evaluating Processes of Care & the Outcomes of Children in Hospital (EPOCH)

Study of Paclitaxel/Carboplatin With or Without Bavituximab in Previously Untreated Non Small-Cell Lung Cancer

An Expanded Access, Open-Label Study of Obinutuzumab (GA101) Plus Chlorambucil in Patients With Previously Untreated Chronic Lymphocytic Leukemia

Study in Pediatrics With Relapsed or Refractory Pediatric Acute Lymphoblastic Leukemia (pALL) or Lymphoblastic Lymphoma

Study of Voreloxin (Vosaroxin) in Older Patients With Untreated Acute Myeloid Leukemia

Phase II Study of VS-6063 in Patients With KRAS Mutant Non-Small Cell Lung Cancer

Daily Everolimus in Combination With Trastuzumab and Vinorelbine in HER2/Neu Positive Women With Locally Advanced or Metastatic Breast Cancer

An Extension Study of RO5045337 in Participants Participating in Previous Roche-sponsored Cancer Studies

Biomarker-based Cockroach Sublingual Immunotherapy Study (BioCSI)

A Phase I, Multicenter, Dose Escalation Study of CAT-8015 in Participants With Chronic Leukemia

Dose Range Study of Anamorelin in Patients With Non-small Cell Lung Cancer

A Bioequivalence Study of Two Oral Formulations of Topotecan in Patients With Advanced Solid Tumors

CNDO-109-AANK for AML in First Complete Remission (CR1)

Bone Marrow Transplantation With Specially Treated Bone Marrow in Treating Patients With Hematologic Cancer That Have Not Responded to Previous Therapy

Other Conditions in Detroit